Loading...
XNAS
AGIO
Market cap1.91bUSD
Oct 08, Last price  
31.92USD
1D
0.41%
1Q
-22.58%
Jan 2017
-23.51%
IPO
14.90%
Name

Agios Pharmaceuticals Inc

Chart & performance

D1W1MN
XNAS:AGIO chart
P/E
—
P/S
35.27
EPS
—
Div yield, %
—
Shrs. gr., 5y
-3.42%
Rev. gr., 5y
-20.91%
Revenues
54m
+48.03%
21,837,00025,106,00025,548,00065,358,00059,119,00069,892,00043,011,00094,387,000117,912,0000014,240,00026,823,00036,498,00054,028,000
Net income
-413m
L
-23,706,000-20,102,000-39,407,000-53,504,000-117,732,000-198,471,000-314,670,000-346,028,000-411,472,000-327,370,0001,604,715,000-231,801,000-352,088,000673,725,000-412,781,000
CFO
-373m
L-4.33%
-15,219,000-49,548,000-56,400,000-59,353,000-76,949,00038,562,000-285,232,000-304,421,000-370,622,000-290,759,000-407,320,000-309,478,000-296,062,000-389,841,000-372,977,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Agios Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of treatments within cellular metabolism and associated biological domains. Its lead product, PYRUKYND (mitapivat), serves as an activator for both healthy and various mutated forms of the pyruvate kinase (PK) enzyme, targeting the management of hemolytic anemias. Additionally, AG-946, an investigational compound, is currently undergoing Phase I clinical evaluation for hemolytic anemias and other conditions. Established in 2007, Agios Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.

Key people

John Maraganore
Chairman of the Board · since 2016
Bruce Car
Chief Scientific Officer · since 2020
Jacqualyn Fouse
Chief Executive Officer, Director · since 2019
David Schenkein
Executive Chairman of the Board · since 2019
Paul Clancy
Independent Director · since 2013
Ian Clark
Independent Director · since 2016
Maykin Ho
Independent Director · since 2015
URL
https://www.agios.com/
IPO date
Jul 24, 2013
Employees
389
Domiciled in
US
Incorporated in
US
Legal address
c/o The Corporation Trust Company, Corporation Trust Center 1209 Orange St
Wilmington, DE 19801
US
Headquarters
88 Sidney Street
Cambridge, MA 02139
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT